Target intelligence / Profile preview

Peptidyl-prolyl cis-trans isomerase FKBP12 F36V-tagged fusion protein (FKBP12(F36V))

Target
FKBP12(F36V)
Molecular classification
Peptidyl-prolyl cis-trans isomerase, Immunophilin, Engineered protein tag
01

Overview

FKBP12 F36V-tagged fusion proteins are engineered protein constructs central to the degradation TAG (dTAG) system, a chemical biology platform used for the rapid and selective depletion of specific proteins. This system employs a mutant version of the human FKBP12 protein, where phenylalanine at position 36 is replaced by valine (F36V), creating a unique binding pocket that accommodates bulky synthetic ligands while avoiding cross-reactivity with endogenous wild-type FKBP12 [1]. These synthetic ligands, known as dTAG molecules, are heterobifunctional degraders (PROTACs) that bind specifically to the FKBP12 F36V tag and simultaneously recruit an E3 ubiquitin ligase, such as Cereblon (CRBN) or Von Hippel-Lindau (VHL) [1, 2]. The resulting ternary complex facilitates the polyubiquitination of the fusion protein, leading to its rapid degradation by the 26S proteasome [2]. This technology is primarily utilized in drug discovery and functional genomics to validate therapeutic targets by providing a means to pharmacologically control protein levels with high temporal precision [3]. While currently a research tool, the dTAG system represents a significant advancement in targeted protein degradation and offers a robust alternative to genetic knockdown or knockout methods [1].

Other names
dTAG systemFKBP12vFKBP12 F36VDegradation TAGFKBP12(F36V) fusion protein
02

Mechanism of action

The target functions as a docking site for heterobifunctional degraders (dTAG ligands). These ligands bridge the FKBP12 F36V-tagged protein and an E3 ubiquitin ligase (e.g., CRBN or VHL), inducing polyubiquitination and subsequent degradation of the fusion protein by the 26S proteasome [1, 2].

03

Biological functions

Targeted protein degradationProtein homeostasis regulationTarget validation
04

Disease associations

CancerResearch tool
05

Safety considerations

Immunogenicity of the mutant tagOff-target degradation of wild-type FKBP12 at high ligand concentrationsDelivery of heterobifunctional molecules
06

Interacting drugs

dTAG-13

4 more in the full profile.

07

Biomarkers

Fusion protein levelsUbiquitination of the FKBP12(F36V) tag

Beyond the preview

Go deeper on Peptidyl-prolyl cis-trans isomerase FKBP12 F36V-tagged fusion protein (FKBP12(F36V)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Peptidyl-prolyl cis-trans isomerase FKBP12 F36V-tagged fusion protein (FKBP12(F36V)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call